NCT03460977 2026-04-16
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
Clinical Trials
1,003 trialsNCT06066138 2026-04-16
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07005128 2026-04-16
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT07229313 2026-04-16
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
Phase 1 Recruiting
NCT07328490 2026-04-16
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
NCT07509034 2026-04-16
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT07532057 2026-04-16
PR-LUNGCA-2019
Istanbul Medipol University Hospital
Phase NA Completed
NCT05616624 2026-04-15
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT06117774 2026-04-15
DeLLphi-306
Amgen
Phase 3 Recruiting
NCT06892548 2026-04-15
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
BioNTech SE
Phase 1/2 Recruiting
NCT07488676 2026-04-15
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT07531095 2026-04-15
DeLLphi-313
Amgen
Phase 1 Not yet recruiting
NCT06077500 2026-04-14
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07155174 2026-04-14
SEZanne
AbbVie
Phase 2 Recruiting
NCT07502300 2026-04-14
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT02595931 2026-04-13
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03540420 2026-04-13
ACHILES
Norwegian University of Science and Technology
Phase 2 Active not recruiting
NCT03896503 2026-04-13
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04079712 2026-04-13
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04553133 2026-04-13
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
NCT04938817 2026-04-13
KEYNOTE-B98
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05353439 2026-04-13
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06227546 2026-04-13
MGC018-SCLC
Georgetown University
Phase 2 Active not recruiting
NCT06500026 2026-04-13
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT06780137 2026-04-13
MK-6070-002
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07057791 2026-04-13
PrE0510
PrECOG, LLC.
Phase 2 Recruiting
NCT07501169 2026-04-13
STAR-01
Sichuan University
Phase 2 Not yet recruiting
NCT07339059 2026-04-09
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
NCT07407933 2026-04-09
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT04660097 2026-04-08
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Completed
NCT04919382 2026-04-08
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT07226999 2026-04-08
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Pfizer
Phase 2/3 Recruiting
NCT07278479 2026-04-08
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners AG
Phase 1/2 Recruiting
NCT07476287 2026-04-08
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Pfizer
Phase 2 Recruiting
NCT07517198 2026-04-08
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
Phase 1 Recruiting
NCT05903092 2026-04-07
MOZART
Hoosier Cancer Research Network
Phase 2 Suspended
NCT06131840 2026-04-07
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT07424547 2026-04-07
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Recruiting
NCT05703269 2026-04-06
HYPOGRYPHE
Wake Forest University Health Sciences
Phase NA Active not recruiting
NCT04256421 2026-04-03
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
NCT04804644 2026-04-03
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NRG Oncology
Phase 3 Recruiting
NCT05957510 2026-04-03
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials
Phase 2 Recruiting
NCT06646276 2026-04-03
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT07509333 2026-04-03
MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients
West China Hospital
Phase NA Recruiting
NCT05879978 2026-04-02
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT06840704 2026-04-02
Relief
Hunan Cancer Hospital
Phase 3 Recruiting
NCT07296809 2026-04-02
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Recruiting
NCT07508852 2026-04-02
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
Peking University First Hospital
Phase 1/2 Recruiting
NCT03923270 2026-04-01
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT06807632 2026-04-01
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting